Product How it works Pricing Blog FAQ About Contact
Iovance Biotherapeutics

Iovance Biotherapeutics (NASDAQ: IOVA) net income

Iovance Biotherapeutics reported a net loss of $391.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $372.2m. Earnings per share were −$1.09.

Iovance Biotherapeutics's best year of the last 10 was fiscal 2016. It reported a loss in 10 of those 10 years.

Net income, in millions of US dollars-52.92016-92.12017-123.62018-197.62019-259.62020-342.32021-395.92022-444.02023-372.22024-391.02025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$391.0m—−148.4%−$1.09
2024−$372.2m—−226.8%−$1.28
2023−$444.0m—−37,345.4%−$1.89
2022−$395.9m——−$2.49
2021−$342.3m——−$2.23
2020−$259.6m——−$1.88
2019−$197.6m——−$1.59
2018−$123.6m———
2017−$92.1m———
2016−$52.9m———

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Iovance Biotherapeutics net income compared with its sector

By net income for its latest fiscal year, Iovance Biotherapeutics ranks 464th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Iovance Biotherapeutics, −148.4%.

RankCompanyNet incomeNet margin
462ndScholar Rock−$377.9m—
463rdIonis Pharmaceuticals−$381.4m−40.4%
464thIovance Biotherapeutics−$391.0m−148.4%
465thagilon health−$391.3m−6.6%
466thGrail−$408.4m−277.5%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Iovance Biotherapeutics

How much did Iovance Biotherapeutics earn in fiscal 2025?
Iovance Biotherapeutics reported a net loss of $391.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $372.2m.
What are the earnings per share of Iovance Biotherapeutics?
They were −$1.09 in fiscal 2025, compared with −$1.28 in fiscal 2024.
Where does Iovance Biotherapeutics rank in its sector by net income?
It ranks 464th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Iovance Biotherapeutics come from?
From the annual report (Form 10-K) that Iovance Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Iovance Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Iovance Biotherapeutics: the Iovance Biotherapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.